Agilent, GKSB-302, AdvanceBio 2-AB G0F / FA2 N-glycan Standard

AdvanceBio 2-AB G0F / FA2 N-glycan Standard. N-glycan (asialo-, agalacto-, biantennary complex, core-substituted with fucose) labeled with 2-aminobenzamide (2-AB), for use as a qualitative standard in applications such as liquid chromatography (LC). Alternative glycan names: F(6)A2, NGA2F.

Specifications:
Chemical Structure:
Label: 2-AB
Monoisotopic Mass: MWGlycan + 120.06875 = 1582.6132
Name: G0F
Oxford Name: F(6)A2
Standard Type: Complex-type Native N-Glycan
Unit: 100 pmol

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
This high-purity N-glycan standard is designed for use in quantitative and qualitative glycan analysis workflows in biopharmaceutical research and quality control. Each vial contains a precisely characterized G0F or FA2 oligosaccharide labeled with 2-aminobenzamide (2-AB), facilitating sensitive fluorescent detection. The well-defined glycan structure ensures accurate calibration, system suitability, and robust method validation when analyzing N-linked glycans from therapeutic proteins, monoclonal antibodies, or biosimilars.

Optimized for use with Agilent’s AdvanceBio Glycan Mapping columns, this reference material supports seamless integration into existing workflows using hydrophilic interaction liquid chromatography HILIC with fluorescence or mass spectrometry detection. Intended for laboratories requiring confident identification and quantification of the G0F glycan, it is suitable for standardizing sample preparation protocols and validating chromatographic performance, enhancing data reliability and regulatory compliance.

The standard complements Agilent’s comprehensive line of glycan sample preparation kits, glycan mAb profiling solutions, and 2-AB labeling reagents. It is fully compatible with Agilent 1200 Infinity Series and 1260 Infinity II LC systems, as well as major third-party HPLC or UHPLC platforms. Suitable for method development, lot-to-lot comparability testing, and in-process monitoring of glycosylation profiles across a range of therapeutic modalities.